bullish

Pharmaessentia Corp (6446 TT): First In-House Drug Approval in the U.S., More to Follow

587 Views25 Nov 2021 23:29
SUMMARY
  • Pharmaessentia Corp (6446 TT) received FDA approval for its rare cancer drug, BESREMi, which has superior clinical efficacy over the existing standard of care.
  • The drug has already been approved in 17 countries in EU, Taiwan, and South Korea. It is also being developed for several other indications, with license expected in next year.
  • BESREMi’s continued success in the EU markets since its launch in 2019 has enhanced my conviction on the commercial accomplishment of BESREMi in the U.S.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
x